CLINICAL TRIALS PROFILE FOR EDARAVONE
✉ Email this page to a colleague
All Clinical Trials for edaravone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00153946 ↗ | Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke | Completed | Japan Cardiovascular Research Foundation | Phase 4 | 2004-08-01 | Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke. |
| NCT00153946 ↗ | Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke | Completed | Combination Therapy for Acute Ischemic Stroke Study Group | Phase 4 | 2004-08-01 | Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke. |
| NCT00200356 ↗ | Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 4 | 2004-08-01 | This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months. |
| NCT00265239 ↗ | Pilot Study of Edaravone to Treat Acute Myocardial Infarction | Completed | Japan Heart Foundation | Phase 4 | 2001-04-01 | Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI. |
| NCT00265239 ↗ | Pilot Study of Edaravone to Treat Acute Myocardial Infarction | Completed | Kumamoto University | Phase 4 | 2001-04-01 | Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI. |
| NCT00330681 ↗ | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 3 | 2006-05-01 | The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients. |
| NCT00415519 ↗ | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III | Completed | Mitsubishi Tanabe Pharma Corporation | Phase 3 | 2006-12-01 | The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients who met severity classification III. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for edaravone
Condition Name
Clinical Trial Locations for edaravone
Trials by Country
Clinical Trial Progress for edaravone
Clinical Trial Phase
Clinical Trial Sponsors for edaravone
Sponsor Name
